Hanmi Pharmaceutical introduced the company’s future vision, including R&D strategy in 2016, to global healthcare investors.
South Korea’s leading pharmaceutical company participated in the 34th JP Morgan Healthcare Conference, which took place from Jan. 11 to 14 (local time) in the U.S., and announced the company’s new drug pipelines and open innovation strategy.
Hosted by the U.S.-based investment bank, the conference was held in Westin St. Francis Hotel in San Francisco, attended by 150 participants.
The JP Morgan Healthcare Conference, which takes place at the beginning of each year, is the largest and oldest health care symposiums in the world. This year, Hanmi Pharm Chairman Lim Sung-ki and CEO Lee Kwan-soon took part in the conference.
In particular, CEO Lee Kwan-soon talked about its new human growth hormone drug, or LAPSrhGH, and 2nd generation RAF inhibitor, or HM95573, based on Hanmi Pharm’s LAPSCOVERY platform technology, as well as its novel drugs, which are currently under global clinical trials, at the event for Investor Relations on Jan. 13.